GILD · Gilead Sciences Inc
United States · RS rating 95 · As of 2026-11-03
| Price | 167.47 USD |
|---|---|
| 1-day change | -1.7% |
| RS rating (overall / 1M / 3M / 12M) | 95 / 90 / 92 / 81 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 50 / 70 / 55 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -28.4% |
| Sales growth Q/Q | +2.0% |
| Distance from 52-week high | +1.9% |
| Market cap (USD) | $165.9B |